A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

Y. Boumber; H. Kantarjian; J. Jorgensen; S. Wen; S. FaDerl; R. Castoro; J. Autry; G. Garcia-Manero; G. Borthakur; E. Jabbour; Z. Estrov; J. Cortes; J. P. Issa; F. Ravandi

doi:10.1038/leu.2012.153

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

Y. Boumber^*, H. Kantarjian, J. Jorgensen, S. Wen, S. FaDerl, R. Castoro, J. Autry, G. Garcia-Manero, G. Borthakur, E. Jabbour, Z. Estrov, J. Cortes, J. P. Issa, F. Ravandi

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

52 Scopus citations

Original language	English (US)
Pages (from-to)	2428-2431
Number of pages	4
Journal	Leukemia
Volume	26
Issue number	11
DOIs	https://doi.org/10.1038/leu.2012.153
State	Published - Nov 2012
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2012.153

Cite this

Boumber, Y., Kantarjian, H., Jorgensen, J., Wen, S., FaDerl, S., Castoro, R., Autry, J., Garcia-Manero, G., Borthakur, G., Jabbour, E., Estrov, Z., Cortes, J., Issa, J. P., & Ravandi, F. (2012). A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission. Leukemia, 26(11), 2428-2431. https://doi.org/10.1038/leu.2012.153

@article{eba1df0e2e514e04a45e91c55032c0f8,

title = "A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission",

author = "Y. Boumber and H. Kantarjian and J. Jorgensen and S. Wen and S. FaDerl and R. Castoro and J. Autry and G. Garcia-Manero and G. Borthakur and E. Jabbour and Z. Estrov and J. Cortes and Issa, {J. P.} and F. Ravandi",

note = "Funding Information: This work was supported in part by the Leukemia SPORE, CA100632 and by a grant from Eisai Pharmaceuticals. Funding Information: We would like to thank Angelo Willems and Carine Seynaeve for their expert technical assistance. The work was financially supported by the International Myeloma Foundation, Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl), Stichting tegen Kanker, King Baudouin Foundation, Multiple Myeloma Research Foundation, the European Stem cell network (EUFP6 MSCNET) and the Onderzoeks-raad Vrije Universiteit Brussel (GOA48, OZR-VUB). E Van Valckenborgh, E Menu and E De Bruyne are postdoctoral fellows, and E Schouppe and K Movahedi are predoctoral fellows of FWO-Vl. JA Van Ginderachter is supported by Stichting tegen Kanker. OT-1 mice were a kind gift of Dr Muriel Moser (ULB, Brussels, Belgium). Non-labeled anti-CCR2 (MC-21) was a gift of Dr Matthias Mack (University of Regensburg, Germany).",

year = "2012",

month = nov,

doi = "10.1038/leu.2012.153",

language = "English (US)",

volume = "26",

pages = "2428--2431",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "11",

}

Boumber, Y, Kantarjian, H, Jorgensen, J, Wen, S, FaDerl, S, Castoro, R, Autry, J, Garcia-Manero, G, Borthakur, G, Jabbour, E, Estrov, Z, Cortes, J, Issa, JP & Ravandi, F 2012, 'A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission', Leukemia, vol. 26, no. 11, pp. 2428-2431. https://doi.org/10.1038/leu.2012.153

TY - JOUR

T1 - A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

AU - Boumber, Y.

AU - Kantarjian, H.

AU - Jorgensen, J.

AU - Wen, S.

AU - FaDerl, S.

AU - Castoro, R.

AU - Autry, J.

AU - Garcia-Manero, G.

AU - Borthakur, G.

AU - Jabbour, E.

AU - Estrov, Z.

AU - Cortes, J.

AU - Issa, J. P.

AU - Ravandi, F.

N1 - Funding Information: This work was supported in part by the Leukemia SPORE, CA100632 and by a grant from Eisai Pharmaceuticals. Funding Information: We would like to thank Angelo Willems and Carine Seynaeve for their expert technical assistance. The work was financially supported by the International Myeloma Foundation, Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO-Vl), Stichting tegen Kanker, King Baudouin Foundation, Multiple Myeloma Research Foundation, the European Stem cell network (EUFP6 MSCNET) and the Onderzoeks-raad Vrije Universiteit Brussel (GOA48, OZR-VUB). E Van Valckenborgh, E Menu and E De Bruyne are postdoctoral fellows, and E Schouppe and K Movahedi are predoctoral fellows of FWO-Vl. JA Van Ginderachter is supported by Stichting tegen Kanker. OT-1 mice were a kind gift of Dr Muriel Moser (ULB, Brussels, Belgium). Non-labeled anti-CCR2 (MC-21) was a gift of Dr Matthias Mack (University of Regensburg, Germany).

PY - 2012/11

Y1 - 2012/11

UR - http://www.scopus.com/inward/record.url?scp=84869095050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869095050&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.153

DO - 10.1038/leu.2012.153

M3 - Letter

C2 - 22665218

AN - SCOPUS:84869095050

SN - 0887-6924

VL - 26

SP - 2428

EP - 2431

JO - Leukemia

JF - Leukemia

IS - 11

ER -

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this